Marty Makary, President Trump's nominee to lead the Food and Drug Administration, declined during his Senate confirmation hearing to say whether the president could ever be wrong, according to reporting by Ars Technica. The exchange quickly drew attention as a signal of how the nominee might navigate the tension between scientific independence and political loyalty at one of the country's most consequential regulatory agencies.
The FDA is not a minor administrative posting. It oversees the safety and efficacy of drugs, vaccines, medical devices, and a substantial portion of the food supply — decisions that touch virtually every American and carry enormous consequences for the pharmaceutical and biotechnology industries. The agency's credibility rests, in large measure, on the perception that its scientists and its leadership make determinations based on evidence rather than on the preferences of whoever happens to occupy the White House. That perception has been under pressure for years, and the confirmation hearing of any FDA commissioner nominee arrives freighted with questions about how much independence the agency can realistically maintain.
The background here matters. Makary is a surgeon and health policy commentator at Johns Hopkins who built a public profile partly by criticizing institutional medicine and regulatory overreach — positions that gave him appeal within circles skeptical of the established public health apparatus. He is not without mainstream credentials, but his public commentary has sometimes placed him at odds with consensus scientific positions, particularly during the COVID-19 pandemic. That history made his nomination both intelligible as a political choice and immediately contentious among researchers and public health professionals who worry about the direction of the agency.
The question of whether a president can be wrong is, on its face, almost comically simple. Of course presidents can be wrong — that is the kind of statement any scientist or regulator should be able to make without flinching, because the entire edifice of evidence-based regulation depends on the principle that empirical reality is not subordinate to political authority. When a nominee declines to affirm that basic premise, it is reasonable to ask what it means for the decisions they would make once confirmed. The likely reading is not that Makary personally believes the president is infallible, but that he calculated — correctly or not — that saying so plainly would create political friction he preferred to avoid. The calculation itself is revealing.
This fits a broader and increasingly visible pattern. Across multiple administrations, but with particular intensity in recent years, the relationship between political appointees and the scientific agencies they lead has grown more fraught. The CDC, the NIH, and the FDA have all faced moments where the question of who ultimately sets the agenda — career scientists or political leadership — became public and damaging. The concern among agency watchers is not that any single nominee is corrupt or incompetent, but that the cumulative effect of nominees who visibly subordinate institutional norms to political signaling gradually erodes the agency's authority with the public and with the scientific community it depends on to function.
For the pharmaceutical and biotech industries, an FDA under uncertain leadership creates a specific kind of risk. Drug approval timelines, clinical trial standards, and the criteria by which new therapies reach patients all depend on predictable, science-driven processes. If manufacturers or investors begin to suspect that regulatory decisions are shaped by factors outside the evidentiary record, the resulting uncertainty can slow investment and, in worst cases, damage the credibility of approvals themselves — making it harder to persuade a skeptical public that a newly approved drug or vaccine is genuinely safe.
For patients and the broader public, the stakes are more direct. An FDA that is perceived as politically pliable is an FDA whose pronouncements carry less weight, and reduced institutional trust has measurable consequences for public health outcomes, as the COVID years demonstrated with painful clarity.
The consequences for Makary personally, in the short term, are probably limited. Confirmation hearings frequently feature evasive answers, and nominees who survive the process often prove more independent in office than their hearings suggested — or less. The record is genuinely mixed, and it would be premature to conclude from a single exchange what kind of commissioner he would be.
What to watch for next is straightforward but important. If confirmed, Makary's early decisions on high-profile drug and vaccine reviews will be the first real test of whether the hearing moment was political caution or a preview of something more structural. The agency's handling of any issue where the White House has expressed a strong public preference — and there are several plausible candidates — will indicate quickly whether the FDA's scientific staff feel empowered to reach conclusions the administration might find inconvenient. That is the signal worth waiting for.
